Gainers
- YS Biopharma Co YS stock rose 43.0% to $1.08 during Thursday's after-market session. Today's trading volume for this security ended up closing at 1.6 million shares, which is 267.1 percent of its average volume over the last 100 days. The company's market cap stands at $100.5 million.
- Lucy Scientific Discovery LSDI shares rose 10.3% to $0.64. The market value of their outstanding shares is at $11.0 million.
- Modular Medical MODD shares moved upwards by 6.25% to $1.36. The company's market cap stands at $28.6 million.
- Adaptimmune Therapeutics ADAP stock rose 6.24% to $0.85. The market value of their outstanding shares is at $192.2 million.
- Omega Therapeutics OMGA shares rose 4.99% to $3.78. The company's market cap stands at $208.4 million.
- Singular Genomics Sys OMIC stock rose 4.99% to $0.49. The market value of their outstanding shares is at $36.1 million.
Losers
- Myomo MYO stock fell 18.7% to $0.61 during Thursday's after-market session. At the close, Myomo's trading volume reached 151.2K shares. This is 39.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $12.8 million.
- Aeglea BioTherapeutics AGLE stock decreased by 10.26% to $0.49. The market value of their outstanding shares is at $49.5 million.
- Minerva Surgical UTRS shares decreased by 8.0% to $0.23. Today's trading volume for this security ended up closing at 1.1 million shares, which is 27.2 percent of its average volume over the last 100 days. The company's market cap stands at $40.8 million.
- SeqLL SQL stock fell 7.92% to $0.3. The company's market cap stands at $4.1 million.
- Nemaura Medical NMRD shares fell 7.6% to $0.55. The company's market cap stands at $15.7 million.
- Cue Health HLTH shares decreased by 7.01% to $0.5. Trading volume for this security closed at 52.2K, accounting for 5.8% of its average full-day volume over the last 100 days. The company's market cap stands at $77.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in